Intratumoral Hypoxia Reduces IFN-γ–Mediated Immunity and MHC Class I Induction in a Preclinical Tumor Model
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Tumor hypoxia occurs because of an increased demand for oxygen by the rapidly growing tumor cells, together with reduction in the oxygen supply due to malformed and nonfunctional tumor vasculature. The effects of tumor hypoxia on radiotherapy (RT) are well known; however, recent findings suggest it may also suppress immunotherapy, although the mechanisms governing this observation remain undetermined. Our laboratory and others have shown that IFN-γ conditions the tumor milieu and is important for the efficacy of RT. Thus, we hypothesized that hypoxia could inhibit IFN-γ–mediated antitumor responses, resulting in decreased RT efficacy. This inhibition could involve the production and/or the cellular response to IFN-γ. To test this, we used murine tumor cell lines B16F0 and Colon38. We observed that hypoxia inhibited upregulation of IFN-γ–dependent MHC class I expression by tumor cells along with the gene expression of IFN-γ–dependent chemokines CXCL9 and CXCL10, essential for immune cell infiltration. Furthermore, CD8+ T cells, an important source of IFN-γ, which mediate effector antitumor responses, had reduced ability to proliferate and generate IFN-γ under hypoxic conditions in vitro. Interestingly, reoxygenation restored the cytokine-producing capability of these cells. Studies performed in vivo using a mouse tumor model and the hypoxia marker EF5 demonstrated that RT could reverse the hypoxia within treated tumors. This study has identified a unique mechanism of hypoxia-induced immune suppression involving the downregulation of IFN-γ production and cellular responsiveness to this essential cytokine. These results suggest that therapies that target and reduce tumor hypoxia can potentially boost antitumor immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical studies have shown that hypoxia induces a decrease in IFN-γ signaling in a mouse CRC model, leading to a decrease in MHC class I molecule expression [211].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [211]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“Strategies such as hyperbaric chambers, angiogenesis inhibitors, and radiosensitizer molecules were developed to improve the oxygenation status of tumors and circumvent the problem of radiation resistance (12).”
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,219 · cited 2×
“RT is widely used to treat a majority of cancers, but the presence of hypoxic regions can result in resistance to RT (4, 8–10).”
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514 · cited 1×
“Importantly, biopsies from lung, colon, brain, ovarian, head and neck, pancreas, prostate, rectum, and stomach cancers have demonstrated correlations with increased expression of hypoxia-induced protein expression and poor patient prognosis (5, 7).”
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376 · cited 1×
“These included the chemokines ccl28 (involved with regulatory T cell migration) (36, 37) and cxc3cl1, which increases tumor cell migration and metastasis by enhancing epithelial-to-mesenchymal transition-like phenotype (38).”
Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Van den Bossche, J., Mack, M., Pipeleers, D., In't Veld, P., De Baetselier, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4672 · Cited by 1,239 · cited 6×
“In addition to Ag-specific activation, T cells undergo extensive proliferation, which occurs initially in the lymph node but also occurs in situ within the TME (44).”
InfluentialHypoxia-Inducible Factors: Master Regulators of Cancer Progression
Schito, L., & Semenza, G. L. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.016 · Cited by 962 · cited 1×
“It is a critical factor involved in tumor invasion and metastasis, dormancy, pH regulation, stem cell differentiation, inflammation, angiogenesis, glucose metabolism, and resistance to radiotherapy (RT) and chemotherapy (3–6).”
Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen
Doedens, A. L., Phan, A. T., Stradner, M. H., Fujimoto, J. K., Nguyen, J. V., Yang, E., Johnson, R. S., & Goldrath, A. W. (2013) · Nature Immunology · doi:10.1038/ni.2714 · Cited by 660 · cited 1×
“Additionally, another study demonstrated increased production of the lytic molecules perforin and granzyme upon constitutive activation of hypoxia inducible factor-1 (HIF-1), the predominate transcription factor for hypoxia signaling, indicating that hypoxic T cells are better killers (28, 29).”
Immunological mechanisms of the antitumor effects of supplemental oxygenation
Hatfield, S. M., Kjaergaard, J., Lukashev, D., Schreiber, T. H., Belikoff, B., Abbott, R., Sethumadhavan, S., Philbrook, P., Ko, K., Cannici, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1260 · Cited by 600 · cited 1×
“Similarly, other in vivo studies demonstrate preferential localization of T cells away from hypoxic tumor zones, suggesting a possible immune escape mechanism used by tumor cells (20–22).”
Cited by
Hypoxia-Driven Immune Escape in the Tumor Microenvironment
Vito, A., El-Sayes, N., & Mossman, K. (2020) · Cells · doi:10.3390/cells9040992 · Cited by 270
Zheng, S., Wang, W., Shen, L., Yao, Y., Xia, W., & Ni, C. (2024) · Experimental Hematology & Oncology · doi:10.1186/s40164-024-00543-1 · Cited by 163
Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter
Hompland, T., Fjeldbo, C. S., & Lyng, H. (2021) · Cancers · doi:10.3390/cancers13030499 · Cited by 179
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Hypoxia and the phenomenon of immune exclusion
Pietrobon, V., & Marincola, F. M. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02667-4 · Cited by 119
Metadata
- Authors
- Murthy, A., Gerber, S. A., Koch, C. J., & Lord, E. M.
- Affiliations
- University of Rochester Medicine (US)
- University of Pennsylvania (US)
- Corresponding author
- Murthy, Aditi
- Venue
- ImmunoHorizons
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-04-01
- Volume
- 3
- Issue
- 4
- Pages
- 149-160
- ISSN
- 2573-7732 (ISSN-L)
- PMC
- PMC8195309
- OpenAlex
- W2942594871
- Cited by
- 36
- References
- 50
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 3 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 4 · 2019: 1
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- ImmunoHorizons (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc)
- Funders
- National Cancer Institute (R01CA028332)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor hypoxia, intratumoral hypoxia, interferon-gamma, MHC class I expression, antitumor immunity, radiotherapy, CD8+ T cells, CXCL9, CXCL10, chemokines, immune cell infiltration, tumor reoxygenation, immunosuppression, B16F0 melanoma, colon cancer cells
- MeSH terms
- Animals, Hypoxia, Disease Models, Animal, Female, Humans, Immunity, Immunohistochemistry, Interferon-gamma, Male, Neoplasms, Histocompatibility Antigens Class I, Biomarkers, Gene Expression Regulation, Neoplastic, CD8-Positive T-Lymphocytes, T-Cell Antigen Receptor Specificity, Cell Line, Tumor, Mice, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intratumoral Hypoxia Reduces IFN-γ–Mediated Immunity and MHC Class I Induction in a Preclinical Tumor Model. https://app.cochat.ai/papers/10.4049/immunohorizons.1900017
- The paper
- Murthy, A., Gerber, S. A., Koch, C. J., & Lord, E. M. (2019). Intratumoral Hypoxia Reduces IFN-γ–Mediated Immunity and MHC Class I Induction in a Preclinical Tumor Model. ImmunoHorizons. https://doi.org/10.4049/immunohorizons.1900017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.